All In Biotech

Drug Trial Radar · NCT02609776

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

751

Actual

Start

May 24, 2016

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

  • AmivantamabDrug

    The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.

  • AmivantamabDrug

    Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.

  • LazertinibDrug

    Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.

  • CarboplatinDrug

    Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.

  • PemetrexedDrug

    Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to Day 28
  2. Part 2: Number of Participants With Adverse Events (AEs) and Serious AEsTime frame: Screening up to follow-up (30 [+7] days after the last dose)
  3. Part 2: Overall Response Rate (ORR)Time frame: Up to End of Treatment Follow (EOT) Up Period (30 [+7] days after the last dose)
  4. Part 2: Duration of Response (DOR)Time frame: Up to EOT Follow Up Period (30 [+7] days after the last dose)
  5. Part 2: Percentage of Participants With Clinical BenefitTime frame: Up to EOT Follow Up Period (30 [+7] days after the last dose)
  6. Trough Serum Concentration (Ctrough) of AmivantamabTime frame: Up to EOT (30 days after last dose)
  7. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of AmivantamabTime frame: Up to EOT (30 days after last dose)

Locations

69 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Duarte, California

  • Site not named

    La Jolla, California

  • Site not named

    Orange, California

  • Site not named

    Santa Monica, California

  • Site not named

    West Hollywood, California

  • Site not named

    Tampa, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Bethesda, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Rochester, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    New York, New York

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Houston, Texas

  • Site not named

    Fairfax, Virginia

  • Site not named

    Camperdown, Australia

  • Site not named

    Heidelberg, Australia

  • Site not named

    Kogarah, Australia

  • Site not named

    Murdoch, Australia

  • Site not named

    Woolloongabba, Australia

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Beijing, China

  • Site not named

    Changchun, China

  • Site not named

    Changsha, China

  • Site not named

    Chengdu, China

  • Site not named

    Chongqing, China

  • Site not named

    Guangong Apt/Yuncheng, China

  • Site not named

    Hangzhou, China

  • Site not named

    Hefei, China

  • Site not named

    Nanchang, China

  • Site not named

    Nanjing, China

  • Site not named

    Wuhan, China

  • Site not named

    Zhengzhou, China

  • Site not named

    Bordeaux, France

  • Site not named

    Dijon, France

  • Site not named

    Lyon, France

  • Site not named

    Marseille, France

  • Site not named

    Paris, France

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.